lyj19721101 2015-07-16 15:12 IP:马鞍山
罕见癌症研究基金会(RCRF),致力于通过战略投资和创新合作进行基础治疗罕见的癌症,和美国文化募捐组织(ATCC),世界上最大的非营利性细胞株库,建立神经内分泌肿瘤细胞株收集目录。肠道良性肿瘤和胰腺神经内分泌肿瘤(PNET)需求一种新疗法的研究和发展,即在体内原发性肿瘤中建立新的细胞株。 为了刺激发展新的良性肿瘤和PNET细胞系,该基金会是高兴地宣布第二次开放竞争十个人奖项:开发人员的第一个新的细胞系在每个疾病(肠道良性肿瘤和PNET)将获得100000美元,开发者的第二,第三,第四,第五个新细胞系在每个疾病将会收到50000美元。原文如下:https://www.innocentive.com/ar/challenge/9933756 The lack of well-validated and widely accepted cell lines derived from intestinal carcinoid and pancreatic neuroendocrine tumors (PNET) is a significant barrier for research and development of new therapies. The Caring for Carcinoid Foundation therefore wishes to launch a second Challenge to stimulate a concerted effort to create a “collection” of well-characterized cell lines that faithfully replicate tumor characteristics and genetics. The Foundation has partnered with the Rare Cancer Research Foundation (RCRF), a foundation dedicated to curing rare cancers through strategic investments and innovative collaborations, and the American Type Culture Collection (ATCC), the world’s largest non-profit cell line repository, to establish a Neuroendocrine Tumor Cell Line collection in their catalog. This is a Reduction-to-Practice Challenge that requires written documentation, detailed description of each cell line, and sample delivery. Source: InnoCentive Challenge ID: 9933756 Challenge Overview This Challenge is intended to encourage innovative approaches to establishing new cell lines from primary tumors that grow slowly in vivo and to publicize new methods as well as availability of the new cell lines for broad, unrestricted use. To stimulate development of new carcinoid and PNET cell lines, the Foundation is pleased to announce its second open competition for up to ten individual prizes: Developers of the first new cell lines in each disease (intestinal carcinoid and PNET) will receive $100,000 each and developers of the second, third, fourth, and fifth new cell lines in each disease will receive $50,000 each. Individual   [更多]
悬赏:
悬赏
¥600000.00
载入中...
lyj19721101 2015-03-13 14:16 IP:马鞍山
弥漫性大B细胞淋巴瘤(DLBCL)是一种最常见的非霍奇金淋巴瘤,诊断病例在美国约占淋巴瘤的30%。它是一种特异质性疾病。由于临床多样性和复杂性,又有新的突变在某些难治性患者身上被发现。阿斯利康需要创建一种弥漫性巨大B细胞淋巴瘤的合适的临床模型。 具体链接在:https://www.innocentive.com/ar/challenge/9933016 AstraZeneca Challenge: Developing Clinically-Relevant Models for Diffuse Large B Cell Lymphoma (DLCBL) TAGS: AstraZeneca, Physical Sciences, Life Sciences, Nature, Requests for Partners and Suppliers, Chemistry, RTP AWARD: See details | DEADLINE: 6/02/15 | ACTIVE SOLVERS: 9 | POSTED: 3/04/15 Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma and accounts for up to 30% of newly diagnosed cases in the United States. It is a heterogeneous disease which in part appears to be driven by chronic activation of key survival pathways. A limited number of DLBCL cell lines are available, however there are gaps, and specific patient subtypes are not represented. To add to the complexity of clinical diversity, new mutations are being identified in certain treatment-resistant patients. AstraZeneca is interested in innovative proposals to create suitable preclinical models of DLBCL. This is a Reduction-to-Practice Challenge that requires a written proposal and experimental proof-of-concept data (and/or sample delivery). The Challenge has a special award structure. Whether creating a model for DLBCL or a model of acquired resistance to ibrutinib, up to $10,000 will be designated for solutions that highlight novel technologies to generate in vitro cell lines, whereas up to $25,000 will be awarded for submissions that successfully utilize patient-derived tissues.   [更多]
悬赏:
悬赏
¥90000.00
载入中...
lyj19721101 2015-06-19 15:47 IP:马鞍山
肝脏疾病是一种由病毒或有毒物连续侵害造成肝脏晚期纤维化的慢性疾病。目前,我们的治疗方法很有限,寻找治疗方法的大多数临床试验都失败了,部分原因是由于缺乏预测肝脏疾病发展的生物标志物。公司需要寻找一种新的生物标志物,对提高疾病的可控性会有很大的帮助,定期监测生物标志物也可以促进临床试验治疗药物的进一步发展。 具体可以查看https://www.innocentive.com/ar/challenge/9933671 Challenge Overview Liver disease represents a worldwide unmet medical need. Although there are various causes, the danger is that the liver will become so damaged that it can no longer function adequately. Whether the insult is a viral infection, chemical injury, or immune-related, liver disease follows a slow and steady progression. Early stage liver disease is characterized by inflammation, which if left untreated, can cause scarring and fibrosis. A healthy liver is capable of repair and regeneration, but when there are architectural changes to the tissue, the damage can no longer be reversed. Biopsies are routinely conducted to diagnose liver fibrosis and cirrhosis. Undergoing this invasive procedure involves significant abdominal pain along with the risk for complications and sampling error. Therefore, many patients are reluctant to have a second biopsy even when it is medically advisable. The Seeker desires a specific and sensitive biomarker(s) that is highly associated with liver fibrosis and could be used as a surrogate for clinical efficacy and ideally, could guide treatment selection. Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on August 17, 2015. Late submissions will not be considered. This is a Theoretical Challenge that requires only a written proposal to be submitted. The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker. To receive an award, Solvers will not be required to transfer their exclusive IP rights to the Seeker. Instead, as further described in the Challenge-Specific Agreement, Solvers will grant to the Seeker a one hundred and eighty (180)-day Exclusivity Period from the deadline [11:59 PM (US Eastern Time) on August 17, 2015] for a non-exclusive   [更多]
悬赏:
悬赏
¥50000.00
载入中...
lyj19721101 2015-04-27 17:05 IP:马鞍山
我们体内以分泌胰岛素来维持胰岛细胞血糖水平和体内平衡。而糖尿病患者的胰岛细胞是缺乏或无效的。没有足够活性的胰岛素,糖尿病患者就无法控制血糖。胰岛移植是一种治疗策略,糖尿病患者需要胰岛素注射来控制他们的疾病,减轻或根除症状。阿斯利康正在寻找一个简单的装置将人类胰岛移植出来,来检测药物的性能。 具体如下网站,https://www.innocentive.com/ar/challenge/9933735 Pancreatic islet beta-cells sense blood sugar levels and secrete insulin to maintain homeostasis. In patients with diabetes, islet beta-cells are either lacking or ineffective. Islet transplantation is a treatment strategy that allows diabetics to reduce or eliminate the need for insulin injections to control their disease. AstraZeneca is searching for a simple device to transplant human islets to facilitate testing of therapeutic agents. This Challenge requires only a written proposal. Source: InnoCentive Challenge ID: 9933735 Challenge Overview Diabetes is a disease of the pancreatic islet cells. Of the four cell types, insulin-producing beta-cells are the most abundant. Without adequate levels of insulin, diabetes patients have difficulty controlling their blood sugar. One alternative to self-administration of medicine is islet transplantation. The procedure involves an infusion of isolated donor islets into the patient. If the graft is accepted, these islets will function to regulate blood glucose levels through the production of insulin. AstraZeneca is searching for a simple device for the transplantation and subsequent retrieval of human islets to support in vivo testing of therapeutic agents. ABOUT THE SEEKER AstraZeneca is a global, research-based, biopharmaceutical company with a focus on five key therapeutic areas: 1) cardiovascular & metabolic diseases, 2) oncology, 3) respiratory, inflammation & autoimmunity, 4) neuroscience, and 5) infection. As an innovation-driven, research organization, AstraZeneca recognizes that great ideas come from many sources. Open innovation is an avenue by which ideas can be shared and AstraZeneca recently launched a pavilion to further its commitment to facilitate the advancement of pharmaceutical   [更多]
悬赏:
悬赏
¥25000.00
载入中...
lyj19721101 2014-12-12 15:02 IP:马鞍山
湿疹是一种慢性皮肤疾病,包括炎症,红肿,痒。许多非处方药品都是从干燥的角度来治疗湿疹的,南昌我们需要处方药物,减轻瘙痒和炎症的症状。现在寻求开发一种用于治疗湿疹的新的解决方案。具体如下:(https://www.innocentive.com/ar/challenge/9933668?challenge=9933668) TAGS: Chemistry, Requests for Partners and Suppliers, Life Sciences, Ideation AWARD: $15,000 USD | DEADLINE: 1/31/15 | ACTIVE SOLVERS: 55 | POSTED: 12/09/14 Eczema is a term that refers to a group of chronic skin conditions that involve inflammation, irritation, and itch. Many over-the-counter products are marketed to persons with eczema for the purpose of gaining relief from the dry, itchy rash. Flare-ups require prescription medications that alleviate the symptoms of itch and inflammation. The Seeker is looking to develop novel solutions for the treatment of eczema. This is an Ideation Challenge with a guaranteed award for at least one submitted solution. Source: InnoCentive Challenge ID: 9933668 Challenge Overview Eczema is a general term for all types of dermatitis. The etiology of eczema remains unknown, although there is evidence to suggest that the cause may be hereditary or linked to environmental triggers. People try many things to treat their eczema and these include over-the-counter remedies, prescription medications, and alternative therapies. Common complaints about these treatments stem from the lack of effectiveness in providing symptom relief. Topical corticosteroids and calcineurin inhibitors are widely used to effectively alleviate itch and inflammation, however, prolonged and inappropriate use can cause permanent changes to the skin such as skin thinning. Therefore, eczema treatment remains an unmet medical need. The Seeker is an independent, research-based pharmaceutical company that desires novel ideas for molecules, which are targeted for other diseases, but may also prove to be beneficial for eczema patients. This is an Ideation Challenge, which has the following unique features: There is a guaranteed award. The awards will be paid to the best   [更多]
悬赏:
悬赏
¥15000.00
载入中...
lyj19721101 2014-12-18 12:56 IP:马鞍山
勃林格殷格翰公司对诊断和治疗慢性阻塞性肺疾病以及重症哮喘患者新方法非常感兴趣。针对慢性阻塞性肺病患者或重症哮喘所造成的呼吸道障碍,他们积极寻求恢复方法并寻找分子靶点开发治疗药物。具体如下:(https://www.innocentive.com/ar/challenge/9933560) Boehringer Ingelheim (the Seeker) is interested in identifying new therapeutic concepts for the treatment of patients with chronic obstructive pulmonary disease (COPD) or severe asthma. The Seeker is specifically searching for molecular targets to develop therapeutic agents for the restoration of the airway epithelial barrier function in patients with COPD or severe asthma. The Seeker is also interested in molecular targets driving the regeneration of the airway epithelium. Submitted solutions that meet the Solution Requirements according to this InnoCentive Challenge Statement will be considered for up to three awards of $15,000 each. However, the Seeker may (i) not award any solution if none of the submitted proposals meets all Solution Requirements or (ii) award only the solution of the highest overall quality with $15,000. The consideration for an award requires the willingness and ability of the Solver to provide the Seeker with a non-exclusive license regarding all intellectual property related to the Challenge according to the terms of the InnoCentive Theroretical (Non-Exclusive-License) Challenge-Specific Agreement. 2. Additional application for Research Funding In addition to consideration for the award(s) Solvers with appropriate qualifications and expertise having access to a suitable research laboratory and equipment can apply for research funding (“Research Funding”) to execute a research plan that is proposed in the submitted solution. The requested funding should not exceed a funding period of 2 years and a total budget of $200,000. The selection of candidates for Research Funding will be conducted after completion of the Challenge, and will require the submission of additional information. The decision to fund research will be at the sole discretion of the Seeker. The Challenge according to No.   [更多]
悬赏:
悬赏
¥15000.00
载入中...
lyj19721101 2014-12-23 13:16 IP:马鞍山
目前,科学家们只能很有限的预测药物不同配方的生物利用度。尽管有广阔的临床前数据的药物,我们利用已知的分子性质和制剂在体内的数据并不能完全预测到药物的溶解性能,使得药品在体内部分的变化引起整个研究项目的变化。需求者对两种配方的10个不同的药物分子已经收集了大量在体外和体内的数据,现在寻求一种模型,能够使用体外数据和仅有的的物化性质预测不同制剂在体内的性能。具体如下:(https://www.innocentive.com/ar/challenge/9933559) The Seeker is looking for ideas on how to use a variety of properties of molecules, and simple laboratory tests on different formulations to predict the change in a drug’s pharmacokinetic performance in biological systems resulting from different formulations. This is an Ideation Challenge with a guaranteed award for at least one submitted solution. Source: InnoCentive Challenge ID: 9933559 Challenge Overview Currently, scientists possess a limited ability to predict the bioavailability of different formulations of drugs despite vast pre-clinical data for the drugs. Utilizing measured properties of molecules and the dissolution performance of formulations to predict in vivo data is complex, and made more so by the inherent variability of in vivo data due partly to the variability of the test subjects. The Seeker has collected a significant amount of in vitro and in vivo data for two formulations each of 10 different molecules and would like Solvers to present ideas on how to use the in vitro data and simple molecular descriptors to predict the in vivo performance of different formulations. This is an Ideation Challenge, which has the following unique features: There is a guaranteed award. The awards will be paid to the best submission(s) as solely determined by the Seeker. The total payout will be $15,000, with at least one award being no smaller than $5,000 and no award being smaller than $1,000. Submission forwarding occurs during the Challenge. Since submissions will be forwarded to the Seeker throughout the Challenge, please make sure you upload only a finished proposal. You can submit an updated version of your proposal only as a new submission. If you submit an updated version of your proposal,   [更多]
悬赏:
悬赏
¥15000.00
载入中...
lyj19721101 2015-06-10 16:43 IP:马鞍山
不能控制其发作的癫痫猝死(SUDEP)是导致年轻人死亡的主要原因。每年超过千分之一的癫痫患者死于猝死,如果是不受控制的癫痫发作,风险会增加一百五十分之一。一种普遍恐惧的意识和持续受到的歧视导致太多的人隐藏自己的癫痫病情而没有接受持续治疗或寻求更有效的治疗方法。这增加了他们癫痫猝死的风险 癫痫基金会帮助机构决心改变这种状况,开展一个创意的宣传活动,鼓励人们寻求最佳的癫痫发作和癫痫发作控制和教育他们自己和他们的家庭以及他们如何可以减轻癫痫猝死的风险。此外,这个活动应该邀请更广泛的医疗保健社区讨论SUDEP,明白不接受持续发作的重要性,并寻找一种更有效的治疗方法。具体(https://www.innocentive.com/ar/challenge/9933717)如下 TAGS: Global Health, Business/Entrepreneurship, Life Sciences, Scientific American, Ideation AWARD: $15,000 USD | DEADLINE: 7/13/15 | ACTIVE SOLVERS: 12 | POSTED: 6/09/15 Sudden unexpected death in epilepsy (SUDEP) is the leading cause of death in young adults who have epilepsy and cannot control their seizures. Each year, more than 1 out of 1,000 people with epilepsy die from SUDEP, and, if seizures are uncontrolled, the risk increases to more than 1 out of 150. A widespread lack of awareness and ongoing fear and discrimination lead too many individuals to hide their epilepsy and to accept ongoing seizures instead of seeking out more effective treatments. This increases their risk of SUDEP. The Epilepsy Foundation SUDEP Institute is determined to change this and is challenging Solvers to come up with ideas for a creative advocacy campaign that encourages people with seizures and epilepsy to seek optimal seizure control and to educate themselves and their families about SUDEP and how they can mitigate its risks. In addition, the campaign should invite the broader health care community to talk about SUDEP, understand the importance of not accepting ongoing seizures, and pursue all effective treatment options. Can you help us to demystify seizures and epilepsy, and empower people with epilepsy? This is an Ideation Challenge with a guaranteed award for at least one submitted solution.   [更多]
悬赏:
悬赏
¥15000.00
载入中...
lyj19721101 2014-12-18 12:55 IP:马鞍山
我们对治疗克罗恩病和溃疡性结肠炎的新的机理和作用点感兴趣,这些可能包括,但不限于,接近病灶或调节菌群,代谢,遗传,后天产生的抗体。新治疗方法可能包括,但不限于,疫苗,基因治疗,和小分子化合物,而免疫抑制除外。理想的途径是先找到IBD发病新机理,再转化为一种治疗新的方法。具体如下:(https://www.innocentive.com/ar/challenge/9933446) Novel Treatment Approaches to Cure Inflammatory Bowel Diseases TAGS: Nature, Chemistry, Life Sciences, Ideation AWARD: $10,000 USD | DEADLINE: 2/16/15 | ACTIVE SOLVERS: 21 | POSTED: 12/16/14 The Seeker for this Challenge desires proposals describing potential approaches for curing Crohn’s disease and ulcerative colitis. The Seeker is interested in novel mechanisms of action that specifically address the pathogenesis of inflammatory bowel diseases (IBD). These may include, but are not limited to, approaches targeting or modulating the microbiota, metabolism, genetic, and epigenetic targets. Platforms may involve, but are not limited to, vaccines, gene therapy, and small molecule compounds. The Seeker is not interested in immunosuppression. Desirable approaches are specifically relevant to the pathogenesis of IBD and can be translated into a cure. This is an Ideation Challenge with a guaranteed award for at least one submitted solution. In addition to the Challenge award, the Seeker is open to establishing potential collaborations with the winning Solver(s) to further investigate proposed mechanisms with the eventual goal of developing a cure for IBD. Source: InnoCentive Challenge ID: 9933446 Challenge Overview The Seeker for this Challenge desires proposals for novel approaches that specifically address the causes of inflammatory bowel diseases (IBD) to enable the development of a cure. The Seeker is interested in unique ideas and new approaches (including gene delivery techniques), but is not interested in approaches that are simply common targets for various immunological conditions. That is, the approach must be specifically relevant to the pathogenesis of IBD and can be translated into a cure. This is an Ideation Challenge, which has   [更多]
悬赏:
悬赏
¥10000.00
载入中...
lyj19721101 2014-11-21 17:29 IP:马鞍山
截止日期:2014年12月31日 已有提案:17件 发布时间:2014年11月18日 已选0个,还需要1个。 具体要求:研究人员需要寻找一种新植入盆腔器官脱垂的治疗方法。这一悬赏只需要一个书面建议。 以下几条信息必须同时满足: 1. 必须在2014年12月31日下午11时59分(美国东部时间)收到,逾期的投标概不受理。只需要提案人一个书面建议提交。解决方领取奖金的同时,必须将其独有的知识产权(IP)的权利转让给举办方。 2.这个悬赏任务是必须寻找一种寻找新植入盆腔器官脱垂的治疗方法。盆腔器官脱垂(POP)是指盆腔器官(膀胱,子宫和直肠)的下降,是由于周围结构支撑的损坏。最近的研究表明,妇女在她们的一生中有12.6%的可能性接受手术治疗脱垂修复。POP手术修复的目的是提供并改善盆腔器官的功能,同时尽量减少复发。然而,网状增强修复有可能需要再次手术,在5年目并发症的妇女6%,约10%将需要再次手术治疗复发性脱垂。所以我们需要一种更好治疗方法才能实现不复发的目标。3、投稿在此网站:https://www.innocentive.com/ar/challenge/9933488   [更多]
悬赏:
悬赏
¥10000.00
载入中...
发布需求,坐等药智客上门
  • 安全可靠,先验收再正式付款
  • 性价比超高,节省一半费用
  • 80%的需求得到了圆满解决
立即发布需求

推荐任务